ERBB2 and gastroesophageal junction adenocarcinoma: Although the clinical efficacy of MMP9 inhibition in PDAC remains to be established, recent observations that selective MMP9 inhibition in combination with mFOLFOX6 showed encouraging clinical activity without additional toxicity in patients with HER2-negative gastric and gastric/gastroesophageal junction adenocarcinomas [48], suggest that MMP9 inhibition may be promising for enhancing combined therapeutic benefits.